3,917.90
+1.61%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pfizer
Its shares trade on NSE under the ticker PFIZER.NS. It has been listed since 9 December 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹25.20bn and net income of ₹7.22bn. At that date it held total assets of ₹49.22bn and shareholders' equity of ₹42.03bn.
Pfizer Ltd. engages in the business of manufacturing, marketing, trading, import and export of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The firm has a portfolio of approximately 150 products across over 15 therapeutic areas. The firm is engaged in manufacturing, marketing, trading and exporting pharmaceutical products. The firm offers a range of products for anti-diabetic, anti-infectives, cardiovascular, dermatology, erectile dysfunction, gastrointestinal (GI), multivitamins, neurology, pain/fever/inflammation and autoimmune disorders, among others. Its products include Trulimax, Vibazime DT, Viagra, Daxid, Tricorex, Mucaine, Diamox, Hetrazan, Enbrel, Ativan, Pacitane, Folvite Tablets, Autrin Capsules, Prevenar 13, Wysolone, Loette, Ovral G, Ovral L, Premarin tablets, Premarin Vaginal Cream, Zosyn, Wymox, Tygacil, Cynomycin, Targit, Cyklokapron and Magnamycin. The firm has its own manufacturing facility at Thane and Goa. The firm has various independent contract/third party manufacturers based across the country.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 9 Dec 1994
- Employees
- 2,285
- Website
- pfizerindia.com ↗
Leadership
Pay as last reported
- Mr. Pradip ShahNon-Executive Non-Independent Chairman of the Board, since 2024₹2.5m
- Mr. Amit AgarwalChief Financial Officer, Executive Director - Finance, since 2024₹34.6m
- Mrs. Meenakshi NevatiaManaging Director, Executive Director, since 2023₹94.8m
- Mr. Sharad GoswamiSenior Director - Policy and Public Affairs
- Dr. Pankaj GuptaSenior Director - Medical Affairs
- Dr. Manish PaliwalSenior Director - Regulatory Affairs
- Mr. Anil PattanshettySenior Director - Business Operations
- Mr. Pazhania RenganExecutive Director - Plant Operations, since 2023₹14.8m
- Mr. Saral GuptaDirector - Commercial Channel and Market Access
- Mr. Prashant MahalingamCategory Lead Internal Medicine & Hospitals
- Ms. Aditi MehtaCategory Lead - Vaccines
- Mr. Nilesh PendseCategory Lead Vaccines
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 67
- Environment
- 57
- Social
- 83
- Governance
- 61
- Direct emissions (scope 1)
- 56 t
- Energy emissions (scope 2)
- 1,619 t
- Women in the workforce
- 15.45682%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pfizer Ltd, a leading pharmaceutical company, has several strengths that contribute to its success in the market. These include:
Weaknesses
- Despite its strengths, Pfizer Ltd faces certain weaknesses that it needs to address to maintain its competitive edge:
Opportunities
- Pfizer Ltd has several opportunities to explore and capitalize on for future growth and expansion:
Threats
- Pfizer Ltd faces certain threats that could potentially hinder its growth and profitability:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.